In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
This finding is particularly noteworthy given that ciliary dysfunction resulting from mutations in genes such as those in the BBS family or ALMS1 represents an established mechanism underlying syndromic forms of hereditary obesity
This level of traceability is a powerful tool for risk management
If you inject once weekly, the vial lasts 12 weeks
District Court for the Northern District of Iowa, alleging that Novo Nordisk and its subsidiaries failed to provide adequate warnings about Ozempic health risks
The recommended dosage and frequency will be determined by your doctor and your bodys ability to store vitamin B12